Moncef Slaoui

Type: Person
Name: Moncef Slaoui
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

GlaxoSmithKline : DIRECTOR DEALINGS: Glaxo Senior Executive Acquires ADSs

LONDON ( Alliance News ) - GlaxoSmithKline PLC Monday said Moncef Slaoui , a divisional chairman, and connected person K Slaoui, bought 5 American Depositary Shares under the GSK 401K plan at a price of USD51.76 per ADS.Glaxo shares were trading at USD51.89 ... [Published 4 Traders - Apr 14 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

GlaxoSmithKline's cancer vaccine MAGE-A3 suffers its second PhIII flop

GlaxoSmithKline's once high-flying hopes in the cancer vaccine MAGE-A3 have crashed to earth--for a second time. Once a top Phase III program at the pharma giant, MAGE-A3 failed to hit a pair of primary endpoints for non-small cell lung cancer, its second ... [Published FierceBiotech - Mar 20 2014]
First reported Feb 27 2014 - Updated Feb 28 2014 - 1 reports

GlaxoSmithKline boss's 2013 bonus doubled despite scandal in China

Sir Andrew Witty's salary rose to £1.06m and he also received benefits of £67,000, as well as share awards worth £3.5m. Photograph: Linda Nylind for the GuardianGlaxoSmithKline 's chief executive, Sir Andrew Witty, doubled his bonus last year, collecting ... [Published Guardian.co.uk - Feb 27 2014]
First reported Feb 05 2014 - Updated Feb 05 2014 - 1 reports

A Spark From GSK

William LooneyDominating the frontier of medicines discovery is a simple, endlessly challenging question: if not a drug, then what? Industryscience has evolved from the chemical roots of the small molecule to the biologics synthesized from living organisms, ... [Published Pharmaceutical Executive - Feb 05 2014]
First reported Jan 06 2014 - Updated Jan 06 2014 - 1 reports

The Pulsing Pharmaceutical: Bioelectronics

GSK Lights a Spark around BioelectronicsDominating the frontier of medicines discovery is a simple, endlessly challenging question: if not a drug, then what?  Industry science has evolved from the chemical roots of the small molecule to the biologics ... [Published Pharmaceutical Executive - Jan 06 2014]
First reported Nov 22 2013 - Updated Nov 22 2013 - 1 reports

GlaxoSmithKline, Amicus enter revised Fabry agreement

GlaxoSmithKline (GSK) and Amicus Therapeutics have announced that Amicus has received global rights for the global drug development, regulatory and commercial activities of migalastat HCl as a monotherapy and in combination with enzyme replacement therapy ... [Published Pharmaceutical Business Review - Nov 22 2013]

More Content

All (7) | News (7) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
GlaxoSmithKline : DIRECTOR DEALINGS: Glaxo Seni... [Published 4 Traders - Apr 14 2014]
GlaxoSmithKline's cancer vaccine MAGE-A3 suffer... [Published FierceBiotech - Mar 20 2014]
GlaxoSmithKline boss's 2013 bonus doubled despi... [Published Guardian.co.uk - Feb 27 2014]
A Spark From GSK [Published Pharmaceutical Executive - Feb 05 2014]
The Pulsing Pharmaceutical: Bioelectronics [Published Pharmaceutical Executive - Jan 06 2014]
GlaxoSmithKline, Amicus enter revised Fabry agr... [Published Pharmaceutical Business Review - Nov 22 2013]
GSK plans US$50m bioelectronic medicine fund [Published TCE Today - Aug 08 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.